Skip to main content
SpringerLink
Log in

Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease

  • Chapter
Book cover International Yearbook of Nephrology 1991

Part of the book series: International Yearbook of Nephrology 1991 ((IYNE,volume 3))

  • 47 Accesses

Abstract

It is well-established that abnormalities in lipoprotein metabolism are associated with an increased risk for atherosclerotic cardiovascular disease (1). Therapeutic strategies designed to reduce circulating lipid levels have also been shown to decrease cardiovascular morbidity and mortality (2, 3). Although these studies have been carried out exclusively in patients with normal renal function, hyperlipidemia is common in patients with renal disease, and the incidence of cardiovascular disease complications is high in this population. Thus, it is important to understand the pathophysiology and treatment of hyperlipidemia in patients with renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The expert panel: Report of the national cholesterol education program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med, 148: 36–69,1988.

    Article  Google Scholar 

  2. Tyroler HA: Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies. Am J Med, 87(suppl 4A): 4A–14S–4A–19S, 1989.

    Google Scholar 

  3. Middeke M, Holzgreve H: Review of major intervention studies in hypertension and hyperlipidemia: focus on coronary heart disease. Am Heart J, 116:1708–1712,1988.

    Article  CAS  Google Scholar 

  4. Rifai N: Lipoproteins and Apolipoproteins. Composition, metabolism and association with coronary heart disease. Arch Pathol Lab Med, 110: 694–701,1986.

    CAS  Google Scholar 

  5. Havel RJ: Lipid transport function of lipoproteins in blood plasma. Am J Physiol, 253 (Endocrinol Metab 16): E1–E5,1987.

    PubMed  CAS  Google Scholar 

  6. Cameron JS, Glassock RJ: The Nephrotic Syndrome: A Historical Review in the Nephrotic Syndrome. New York, Marcel Dekker Inc., 1988, pp. 3–56.

    Google Scholar 

  7. Jungst D, Caselmann H, Kutschera P, Weisweiler P: Relation of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrtic syndrome. Clin Chim Acta, 168: 159–167, 1987.

    Article  PubMed  CAS  Google Scholar 

  8. Short CD, Durrington PN, Mallick NP, Hunt LP, Tetlow L, Ishola M: Serum and urinary high density lipoproteins in glomerular disease with proteinuria. Kidney Int, 29: 1224–1228,1986.

    Article  PubMed  CAS  Google Scholar 

  9. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS: The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med, 312: 1544–1548,1985.

    Article  PubMed  CAS  Google Scholar 

  10. Muls E, Rosseneu M, Daneeis R, Schurgers M, Boelaert J: Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis, 54: 225–237, 1985.

    Article  PubMed  CAS  Google Scholar 

  11. Oetliker OH, Mordasini R, Lutschg J, Riesen W: Lipoprotein metabolism in nephrotic syndrome in childhood. Pediatr Res, 14: 64–66,1980.

    PubMed  CAS  Google Scholar 

  12. Khanna UB, Nerurkar SV, Almeida AF, Taskar SP, Acharya VN: Study of hyperlipidemia in adults with nephrotic syndrome. J Postgrad Med, 31: 140–145,1985.

    PubMed  CAS  Google Scholar 

  13. Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepard J: Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism, 39: 187–192, 1990.

    Article  PubMed  CAS  Google Scholar 

  14. Gitlin D, Comwell DG, Nakasato D, Oncley JL, Hughes WL JR, Janeway CA: Studies on the metabolism of plasma proteins in the nephrotic syndrome. II. The lipoproteins. J Clin Invest, 37: 172–184, 1958.

    Article  CAS  Google Scholar 

  15. Vega GL, Grundy SM: Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int, 33: 1160–1168,1988.

    Article  PubMed  CAS  Google Scholar 

  16. Golper TA, Swartz SH: Impaired renal mevalonate metabolism in nephrotic syndrome: A stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia. Metabolism, 31: 471–476, 1982.

    Article  PubMed  CAS  Google Scholar 

  17. Joven J, Masana L, Villabona C, Vilella E, Bargallo T, Trias M, Figueras M, Turner PR: Low density lipoprotein metabolism in rats with puromycin aminonucleoside-induced nephrotic syndrome. Metabolism, 38: 491–495, 1989.

    Article  PubMed  CAS  Google Scholar 

  18. Kashyap ML, De Mendoza SG, Cambell M, Chen CY, Lutmer RF, Glueck CJ: Lipoprotein lipase activator deficiency in very low density lipoproteins in rat nephrotic syndrome. Experientia, 34: 1044–1045, 1978.

    Article  PubMed  CAS  Google Scholar 

  19. Saku K, Mendoza SG, Laver M, Hynd BA, Gartside PS, Kashyap ML: High-density lipoprotein apolipoprotein AI and All turnover in moderate and severe proteinuria. Nephron, 50: 112–115, 1988.

    Article  PubMed  CAS  Google Scholar 

  20. Berlyne M, Mallick NP: Ischaemic heart disease as a complication of nephrotic syndrome. Lancet, 2: 399–400,1969.

    Article  PubMed  CAS  Google Scholar 

  21. Alexander JH, Schapel GJ, Edwards KD: Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust, 2: 119–122,1974.

    PubMed  CAS  Google Scholar 

  22. Gilboa N: Incidence of coronary heart disease associated with nephrotic syndrome. Med J Aust, 1: 207–209, 1976.

    PubMed  CAS  Google Scholar 

  23. Wass VJ, Jarrett RJ, Chilvers C, Cameron JS: Does the nephrotic syndrome increase the risk of cardiovascular disease?. Lancet, 2: 664–667,1979.

    Article  PubMed  CAS  Google Scholar 

  24. Ordonez JD, Hiatt R, Killebrew E, Fireman B: The risk of cornary artery disease among patients with the nephrotic syndrome. Kidney Int, 37: 243,1990 (abstract).

    Google Scholar 

  25. Iida H, Izumino K, Asaka M, Fujita M, Nishino A, Sasayama S: Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. Nephron, 47: 280–283,1987.

    Article  PubMed  CAS  Google Scholar 

  26. Valeri A, Gelfand J, Blum C, Appel GB: Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis, 8: 388–396,1986.

    PubMed  CAS  Google Scholar 

  27. Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE: Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int, 36: 266–271,1989.

    Article  PubMed  CAS  Google Scholar 

  28. Eisalo A, Manninen V, Mälkönen M Kuhlbäck B: Hypolipidaemic action of gemfibrozil in adult nephrotics. Proc R Soc Med, 69: 47–48,1976.

    PubMed  Google Scholar 

  29. Golper TA, Illingworth DR, Morris CD, Bennett WM: Lovastatin in the treatment of multtfactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis, 13: 312–320,1989.

    PubMed  CAS  Google Scholar 

  30. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendörfer A, Keane WF: The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis, 15: 8–15, 1990.

    PubMed  CAS  Google Scholar 

  31. Rabelink AJ, Erkelens DW, Hene RJ, Joles JA, Koomans HA: Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet, 2: 1335–1338,1988.

    Article  PubMed  CAS  Google Scholar 

  32. Grützmacher P, Radtke HW, Schifferdecker E, Peschke B, Riepenhausen J, Fassbinder W, Schoeppe W: Early changes of plasma lipid status and glucose tolerance during the course of chronic renal failure. Contrib Nephrol, 41: 332–336,1984.

    PubMed  Google Scholar 

  33. Frank WM, Rao TKS, Manis T, Delano BG, Avram MM, Saxena AK, Carter AC, Friedman EA: Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis. Am J Clin Nutr, 31: 1886–1892, 1978.

    PubMed  CAS  Google Scholar 

  34. Grützmacher P, März W, Peschke B, Gross W, Schoeppe W: Lipoproteins and apolipoproteins duri0ng the progression of chronic renal disease. Nephron, 50:103–111,1988.

    Article  PubMed  Google Scholar 

  35. Camejo G, Riera G, Lee M, López F: Lipoprotein structural abnormalities in chronic renal failure with and without hemodialysis. Biomed Biochim Acta, 47: 239–245,1988.

    PubMed  CAS  Google Scholar 

  36. Norbeck HE, Carlson LA: Increased frequency of late pre-B lipoproteins in isolated serum very low density lipoproteins in uraemia. Eur J Clin Invest, 10: 423–426, 1980.

    Article  PubMed  CAS  Google Scholar 

  37. Nestel PJ, Fidge NH, Tan MH: Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med, 307: 329–333, 1982.

    Article  PubMed  CAS  Google Scholar 

  38. Asayama K, Ito H, Nakahara C, Hasegawa A, Kato K: Lipid profiles and lipase activities in children and adolescents with chronic renal failure treated conservatively or with hemodialysis or transplantation. Pediatr Res, 18: 783–788,1984.

    Article  PubMed  CAS  Google Scholar 

  39. Chan MK, Persaud J, Varghese Z, Moorhead JF: Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int, 25: 812–818,1984.

    Article  PubMed  CAS  Google Scholar 

  40. Reaven GM, Swenson RS, Sanfilippo ML: An inquiry into the mechanism of hypertriglyceridemia in patients with chronic renal failure. Am J Clin Nutr, 33: 1476–1484, 1980.

    PubMed  CAS  Google Scholar 

  41. Staprans I, Felts JM, Zacherle B: Apoprotein composition of plasma lipoproteins in uremic patients on hemodialysis. Clin Chim Acta, 93: 135–143, 1979.

    Article  PubMed  CAS  Google Scholar 

  42. Rapoport J, Aviram M, Chaimovitz C, Brook JG: Defective high-density lipoprotein composition in patients on chronic hemodialysis. N Engl J Med, 299: 1326–1329,1978.

    Article  PubMed  CAS  Google Scholar 

  43. Chan MK, Ramdial L, Varghese Z, Persaud JW, Baillod RA, Moorhead JF: Plasma lecithin-cholesterol acyltransferase activities in uraemic patients. Clin Chim Acta 119:65–72,1982.

    Article  PubMed  CAS  Google Scholar 

  44. Jung K, Neumann R, Precht K, Nugel E, Scholz D: Lecithin: cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis. Enzyme, 25: 273–275,1980.

    PubMed  CAS  Google Scholar 

  45. Dieplinger H, Schoenfeld PY, Fielding CJ: Plasma cholesterol metabolism in end-stage renal disease. J Clin Invest, 77: 1071–1083,1986.

    Article  PubMed  CAS  Google Scholar 

  46. Libels LS, Stewart JH, Mahony JF, Neale FC, Sheil AGR: Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. Q J Med, 46: 197–214,1977.

    Google Scholar 

  47. Lowrie EG, Lazarus JM, Mocelin AJ, Bailey GL, Hampers CL, Wilson RE, Merrill JP: Survival of patients undergoing chronic hemodialysis and renal transplantation. N Engl J Med, 288: 863–867, 1973.

    Article  PubMed  CAS  Google Scholar 

  48. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med, 290: 697–700, 1974.

    Article  PubMed  CAS  Google Scholar 

  49. Loschiavo C, Ferrari S, Panebianco R, Bedogna V, Oldrizzi L, Bonazzi L, Maschio G: Effect of protein-restricted diet on serum lipids and atherosclerosis risk factors in patients with chronic renal failure. Clin Nephrol, 29: 113–118, 1988.

    PubMed  CAS  Google Scholar 

  50. Sanfelippo ML, Swenson RS, Reaven GM: Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int, 11: 54–61,1977.

    Article  PubMed  CAS  Google Scholar 

  51. Gokal R, Mann JI, Oliver DO, Ledingham JGG, Carter RD: Treatment of hyperlipidaemia in patients on chronic haemodialysis. Brit Med J, 1: 82–83,1978.

    Article  CAS  Google Scholar 

  52. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA: Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med, 301: 1073–1076,1979.

    Article  PubMed  CAS  Google Scholar 

  53. Sherrard DJ, Goldberg AB, Haas LB, Brunzell JD: Chronic clofibrate therapy in maintenance hemodialysis patients. Nephron, 25: 219–221, 1980.

    Article  PubMed  CAS  Google Scholar 

  54. Pierides AM, Alvarez-Ude F, Kerr DNS, Skillen AW: Clofibrate induced muscle damage in patients with chronic renal failure. Lancet, 2: 1279–1282,1975.

    Article  PubMed  CAS  Google Scholar 

  55. Rumpf KW, Albers R, Scheler F: Clofibrate-induced myopathy syndrome. Lancet, 1: 249–250, 1976.

    Article  PubMed  CAS  Google Scholar 

  56. Committee of Principal Investigators World Health Organization Cooperative Trial: A cooperative trial in the primary prevention of ischemie heart disease using clofibrate. Brit Heart J. 40: 1069–1118,1978.

    Article  Google Scholar 

  57. Pasternack A, Vänttinen T, Solakivi T, Kuusi T, Korte T: Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol, 27: 163–168,1987.

    PubMed  CAS  Google Scholar 

  58. Azar R, Dequiedt F, Awada J, Dequiedt P, Tacquet A: Effects of fish oil rich in polyunsaturated fatty acids on hyperlipidemia of hemodialysis patients. Kidney Int, 27 (Suppl 27): S239–S242, 1989.

    Google Scholar 

  59. Rylance PB, Gordge MP, Saynor R, Parson V, Weston MJ: Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients. Nephron, 43: 196–202, 1986.

    Article  PubMed  CAS  Google Scholar 

  60. Lindholm B, Norbeck HE: Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand, 220:143–151,1986.

    Article  PubMed  CAS  Google Scholar 

  61. Sniderman A, Cianflone K, Kwiterovich PO, Hutchinson T, Barre P, Prichard S: Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis, 565: 257–264,1987.

    Article  Google Scholar 

  62. Ramos JM, Heaton A, Mcgurk JG, Ward MK, Kerr DNS: Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron, 35: 20–23,1983.

    Article  PubMed  CAS  Google Scholar 

  63. Steele J, Billington T, Janus E, Moran J: Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis, 79: 47–50, 1989.

    Article  PubMed  CAS  Google Scholar 

  64. Chan MK, Varghese Z, Persaud JW, Baillod RA, Moorhead JF: Hyperlipidemia in patients on maintenance hemo-and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol, 17:183–190,1982.

    PubMed  CAS  Google Scholar 

  65. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int, 37: 980–990, 1990.

    Article  PubMed  CAS  Google Scholar 

  66. Gokal R, King J, Bogle S, Marsh F, Oliver D, Jakubowski C, Hunt L, Baillod R, Ogg C, Ward M: Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicenter study. Lancet, 2: 1105–1109,1987.

    Article  PubMed  CAS  Google Scholar 

  67. Lempert KD, Rogers JS II, Albrink MJ: Effects of dietary fish oil on serum lipids and blood coagulation in peritoneal dialysis patients. Am J Kidney Dis, 11: 170–175,1988.

    PubMed  CAS  Google Scholar 

  68. Kasiske BL, Urnen AJ: Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore), 66: 309–316, 1987.

    CAS  Google Scholar 

  69. Gokal R, Mann JI, Moore RA, Morris PJ: Hyperlipidaemia following renal transplantation. A study of the prevalence, ‘natural history’ and dietary treatment. Q J Med, 48: 507–517,1979.

    PubMed  CAS  Google Scholar 

  70. Lowry RP, Soltys G, Mangel R, Kwiterovitch P, Sniderman AD: Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors. Transplant Proc, 19: 2229–2232, 1987.

    PubMed  CAS  Google Scholar 

  71. Stern MP, Kolterman OG, Fries JF, Mcdevitt HO, Reaven GM: Adrenocortical steroid treatment of rheumatic diseases. Arch Intern Med, 132: 97–101,1973.

    Article  PubMed  CAS  Google Scholar 

  72. Ettinger WH, Klinefelter HF, Kwiterovitch PO: Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis, 63: 167–172,1987.

    Article  PubMed  CAS  Google Scholar 

  73. Savdie E, Gibson JC, Crawford GA, Simons LA, Mahony JF: Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia. Kidney Int, 18: 774–782, 1980.

    Article  PubMed  CAS  Google Scholar 

  74. Taskinen M-R, Nikkilä EA, Pelkonen R, Sane T: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing’s Syndrome. J Clin Endocrinol Metab, 57: 619–625, 1983.

    Article  PubMed  CAS  Google Scholar 

  75. Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG: Effect of altemate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int, 22:42–47,1982.

    Article  PubMed  CAS  Google Scholar 

  76. Turgan C, Russell GI, Baker F, Walls J: The effect of renal transplantation with a minimal steroid regime on uraemic hypertriglyceridaemia. Q J Med, LIII: 271–277,1984.

    Google Scholar 

  77. Raine AEG, Carter R, Mann JI, Morris PJ: Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant, 3: 458–463,1988.

    PubMed  CAS  Google Scholar 

  78. Harris KPG, Russell GI, Parvin SD, Veitch PS, Walls J: Alterations in lipid and carbohydrate metabolism attributable cyclosporin A in renal transplant recipients. Brit Med J, 292: 16–16, 1986.

    Article  CAS  Google Scholar 

  79. Ibels LS, Stewart JH, Mahony JF, Sheil AGR: Deaths from occlusive arterial disease in renal allograft recipients. Br Med J, 3: 552–554,1974.

    Article  PubMed  CAS  Google Scholar 

  80. Washer GF, Schroeter GPJ, Starzl TE, Weil R: Causes of death after kidney transplantation. JAMA, 250: 49–54, 1983.

    Article  PubMed  CAS  Google Scholar 

  81. Kasiske BL: Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med, 84: 985–992,1988.

    Article  PubMed  CAS  Google Scholar 

  82. Disler PB, Goldberg RB, Kuhn L, Meyers AM, Joffe BI, Seftel HC: The role of diet in the pathogenesis and control of hyperlipidemia after renal transplantation. Clin Nephrol, 16: 29–34, 1981.

    PubMed  CAS  Google Scholar 

  83. Shen SY, Lukens CW, Alongi SV, Sfeir RE, Dagher FJ, Sadler JH: Patient profile and effect of dietary therapy on post-transplant hyperlipidemia. Kidney Int [Suppl], 16: 147–152,1983.

    Google Scholar 

  84. Nelson J, Beauregard H, Gelinas M, St-Louis G, Daloze P, Smeesters C, Corman J: Rapid improvement of hyperlipidemia in kidney transplant patients with a multifactorial hypolipidemic diet. Transplant Proc, 20: 1264–1270,1988.

    PubMed  CAS  Google Scholar 

  85. Moore RA, Callahan MF, Cody M, Adams PL, Litchford M, Buckner K, Galloway J: The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation. Transplantation, 49: 60–62,1990.

    Article  PubMed  CAS  Google Scholar 

  86. Keogh A, Day R, Critchley L, Duggin G, Baron D: The effect of food and cholestyramine in the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc, XX: 27–30,1988.

    Google Scholar 

  87. Tikkanen MJ, Helve E, Jäättelä A, Kaarsalo E, Lehtonen A, Malbecq W, Oksa H, Pääkkönen P, Salmi M, Veharanta T, Viikari J, Äärynen M: Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The Finnish multicenter study. Am J Cardiol, 62: 35J–43J, 1988.

    Article  PubMed  CAS  Google Scholar 

  88. The Lovastatin Study Group: A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA, 260: 359–366,1988.

    Article  Google Scholar 

  89. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Goryance JM, Rao KV: Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation, 49: 95–100,1990.

    Article  PubMed  CAS  Google Scholar 

  90. Norman DJ, Illingworth DR, Munson J, Hosenpud J: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med, 318: 4647,1988.

    Google Scholar 

  91. East C, Alivizato PA, Grundy SM, Jones PH, Farmer JA: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med, 318:47–48,1988.

    Article  PubMed  CAS  Google Scholar 

  92. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB: Rhabdomyolysis and renal injury with lovastatin use. JAMA, 260: 239–241,1988.

    Article  PubMed  CAS  Google Scholar 

  93. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF; Treatment of hyperlipidemia reduces glomerular injuxy in obese Zucker rats. Kidney Int, 33: 667–672,1988.

    Article  PubMed  CAS  Google Scholar 

  94. Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Cire Res, 62: 367–374, 1988.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Minnesota College of Medicine, Hennepin County Medical Center, Minneapolis, MN, 55415, USA

    Bertram L. Kasiske & William F. Keane

Authors
  1. Bertram L. Kasiske
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William F. Keane
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nephrology, University of Naples, Naples, Italy

    Vittorio E. Andreucci

  2. Division of Nephrology, UCLA School of Medicine, University of California, Los Angeles, California, USA

    Leon G. Fine

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Kasiske, B.L., Keane, W.F. (1990). Causes, Consequences, and Treatment of Hyperlipidemia in Patients with Renal Disease. In: Andreucci, V.E., Fine, L.G. (eds) International Yearbook of Nephrology 1991. International Yearbook of Nephrology 1991, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3946-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3946-9_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6761-1

  • Online ISBN: 978-1-4615-3946-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation